
Anemia commonly accompanies malignancies in patients and may contribute to morbidity. Correction of the anemia with erythropoietic stimulating agents, while possible, may be associated with complications such as tumor progression and adverse cardiovascular events. This review examines the data behind these concerns and raises the strategy of using iron, alone, in the setting of cancer-associated anemia to reduce exposure to transfusions in these patients and to potentially improve their quality of life.

